Paolo Baldo (P Baldo)

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 15

Top Topics

Advanced Non Small Cell Lung Cancer

Clinical Practice

Top Venues

International journal of clinical pharmacy

Pharmaceuticals (Basel, Switzerland)

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Anna Parzianello, Giulia Fornasier, Valentina Kiren, Federico Pigato, Sabrina Orzetti, Giulia Zamagni, Anna Arbo, Paolo Baldo, Paola Rossi, Marco Rabusin, Maurizio Mascarin, Marta Paulina Trojniak
Improving Drug Safety in Pediatric and Young Adult Patients with Hemato-Oncological Diseases: A Prospective Study of Active Pharmacovigilance. Pharmaceuticals (Basel, Switzerland) 17 (1) (2024)
Anna Parzianello, Giulia Fornasier, Valentina Kiren, Federico Pigato, Sabrina Orzetti, Giulia Zamagni, Anna Arbo, Paolo Baldo, Paola Rossi, Marco Rabusin, Maurizio Mascarin, Marta Paulina Trojniak
Improving Drug Safety in Pediatric and Young Adult Patients with Hemato-Oncological Diseases: A Prospective Study of Active Pharmacovigilance. Pharmaceuticals (Basel, Switzerland) 17 (1) (2024)
Alessandro Cafaro, Flavia Foca, Oriana Nanni, Marco Chiumente, Marina Coppola, Alberto Russi, Elena Svegliati, Paolo Baldo, Sabrina Orzetti, Fiorenza Enrico, Federico Foglio, Davide Pinnavaia, Vito Ladisa, Claudia Lauria Pantano, Rosa Lerose, Patrizia Nardulli, Simona Ferraiuolo, Piera Maiolino, Immacolata De Stasio, Federica Gradellini, Anna Rita Gasbarro, Rossella Santeramo, Gisella Carrucciu, Riccardo Provasi, Mario Cirino, Paola Cristina Cappelletto, Elisabetta Fonzi, Alessandra Pasqualini, Stefano Vecchia, Marianna Veraldi, Adele Emanuela De Francesco, Lucio Crinò, Angelo Delmonte, Carla Masini
Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (" PEMBROREAL " Study). Cancers 16 (10) (2024)
Alessandro Cafaro, Flavia Foca, Oriana Nanni, Marco Chiumente, Marina Coppola, Alberto Russi, Elena Svegliati, Paolo Baldo, Sabrina Orzetti, Fiorenza Enrico, Federico Foglio, Davide Pinnavaia, Vito Ladisa, Claudia Lauria Pantano, Rosa Lerose, Patrizia Nardulli, Simona Ferraiuolo, Piera Maiolino, Immacolata De Stasio, Federica Gradellini, Anna Rita Gasbarro, Rossella Santeramo, Gisella Carrucciu, Riccardo Provasi, Mario Cirino, Paola Cristina Cappelletto, Elisabetta Fonzi, Alessandra Pasqualini, Stefano Vecchia, Marianna Veraldi, Adele Emanuela De Francesco, Lucio Crinò, Angelo Delmonte, Carla Masini
Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (" PEMBROREAL " Study). Cancers 16 (10) (2024)
Anna Parzianello, Giulia Fornasier, Valentina Kiren, Federico Pigato, Sabrina Orzetti, Giulia Zamagni, Anna Arbo, Paolo Baldo, Paola Rossi, Marco Rabusin, Maurizio Mascarin, Marta Paulina Trojniak
Improving Drug Safety in Pediatric and Young Adult Patients with Hemato-Oncological Diseases: A Prospective Study of Active Pharmacovigilance. Pharmaceuticals (Basel, Switzerland) 17 (1) (2024)
Sabrina Orzetti, Paolo Baldo
Toxicity Derived from Interaction between Natural Compounds and Cancer Therapeutic Drugs Metabolized by CYP3A4: Lessons Learned from Two Clinical Case Reports. International journal of molecular sciences 24 (21) (2023)
Paolo Baldo, Valli De Re, Mattia Garutti
How will the identification and therapeutic intervention of genetic targets in oncology evolve for future therapy? Expert opinion on therapeutic targets (2023)
Andrea Ossato, Vera Damuzzo, Paolo Baldo, Daniele Mengato, Marco Chiumente, Andrea Messori
Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression-free survival based on reconstructed individual patient data. Cancer medicine (2022)
Sabrina Orzetti, Federica Tommasi, Antonella Bertola, Giorgia Bortolin, Elisabetta Caccin, Sara Cecco, Emanuela Ferrarin, Elisa Giacomin, Paolo Baldo
Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice. International journal of molecular sciences 23 (6) (2022)
Diana Crestan, Marta Paulina Trojniak, Sara Francescon, Giulia Fornasier, Paolo Baldo
Pharmacovigilance of anti-cancer medicines: opportunities and challenges. Expert opinion on drug safety 19 (7) (2020)
Giulia Fornasier, Sara Francescon, Roberto Leone, Paolo Baldo
An historical overview over Pharmacovigilance. International journal of clinical pharmacy 40 (4) (2018)
Sara Francescon, Giulia Fornasier, Paolo Baldo
EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies. International journal of clinical pharmacy 40 (4) (2018)
Paolo Baldo, Giulia Fornasier, Laura Ciolfi, Ivana Sartor, Sara Francescon
Pharmacovigilance in oncology. International journal of clinical pharmacy 40 (4) (2018)
G Fornasier, M Taborelli, S Francescon, J Polesel, M Aliberti, P De Paoli, Paolo Baldo
Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance. International journal of clinical pharmacy 40 (4) (2018)
Paolo Baldo, Sara Francescon, Giulia Fornasier
Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology. International journal of clinical pharmacy 40 (4) (2018)